{"id":"ticagrelor-60","safety":{"commonSideEffects":[{"rate":"3-5","effect":"Bleeding"},{"rate":"2-4","effect":"Bradycardia"},{"rate":"1-3","effect":"Dyspnea"},{"rate":"1-2","effect":"Ventricular pauses"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ticagrelor binds to the P2Y12 adenosine diphosphate (ADP) receptor on platelets, preventing platelet activation and aggregation. This antiplatelet effect reduces the risk of stent thrombosis and cardiovascular events in patients with acute coronary syndrome or those requiring percutaneous coronary intervention. The 60 mg dose is a lower maintenance dose used for long-term secondary prevention in certain patient populations.","oneSentence":"Ticagrelor 60 mg is a P2Y12 platelet receptor antagonist that inhibits platelet aggregation and reduces thrombotic events.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:12:35.885Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (ACS) for prevention of thrombotic cardiovascular events"},{"name":"Secondary prevention of atherothrombotic events in patients with prior myocardial infarction"}]},"trialDetails":[{"nctId":"NCT06228456","phase":"PHASE4","title":"Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention","status":"RECRUITING","sponsor":"University of Florida","startDate":"2024-04-01","conditions":"Coronary Artery Disease","enrollment":50},{"nctId":"NCT05785897","phase":"NA","title":"STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT","status":"RECRUITING","sponsor":"IGLESIAS Juan Fernando","startDate":"2025-11-01","conditions":"ST Elevation Myocardial Infarction","enrollment":350},{"nctId":"NCT05650411","phase":"NA","title":"Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM)","status":"NOT_YET_RECRUITING","sponsor":"IGLESIAS Juan Fernando","startDate":"2026-03-01","conditions":"Left Main Coronary Artery Stenosis","enrollment":828},{"nctId":"NCT07268859","phase":"NA","title":"Effect of Fan Application in Preventing Ticagrelor-Associated Dyspnea","status":"RECRUITING","sponsor":"Acibadem University","startDate":"2025-03-15","conditions":"Acute Coronary Syndromes, Ticagrelor, Dyspnea","enrollment":110},{"nctId":"NCT04755387","phase":"PHASE4","title":"Ticagrelor De-escalation Strategy in AMI Patients","status":"RECRUITING","sponsor":"Dong-A University","startDate":"2023-03-27","conditions":"Acute Myocardial Infarction","enrollment":2312},{"nctId":"NCT04483583","phase":"PHASE4","title":"Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI","status":"COMPLETED","sponsor":"University of Florida","startDate":"2020-12-08","conditions":"Coronary Artery Disease","enrollment":81},{"nctId":"NCT07080684","phase":"PHASE4","title":"Short-Term Dual Antiplatelet Therapy With Early Transi-tion to Low-dose Antiplatelet Monotherapy Using Ti-cagRelor in Chronic Coronary Artery Disease","status":"NOT_YET_RECRUITING","sponsor":"University of Messina","startDate":"2025-12-01","conditions":"Chronic Coronary Syndrome","enrollment":1000},{"nctId":"NCT03430661","phase":"PHASE1","title":"A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects","status":"COMPLETED","sponsor":"Viatris Innovation GmbH","startDate":"2018-01-24","conditions":"Healthy","enrollment":77},{"nctId":"NCT03465644","phase":"PHASE4","title":"TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI","status":"COMPLETED","sponsor":"Duk-Woo Park, MD","startDate":"2019-02-12","conditions":"Coronary Stenoses","enrollment":2018},{"nctId":"NCT06653348","phase":"PHASE2, PHASE3","title":"Ticagrelor Based De-Escalation of Dual Antiplatelet Therapy in Ischemic Stroke","status":"RECRUITING","sponsor":"Mazandaran University of Medical Sciences","startDate":"2024-04-01","conditions":"Ischemic Stroke, Transient Ischemic Attack","enrollment":100},{"nctId":"NCT04484259","phase":"PHASE4","title":"Ticagrelor With and Without Aspirin in Patients With Diabetes Mellitus","status":"COMPLETED","sponsor":"University of Florida","startDate":"2021-03-31","conditions":"Diabetes Mellitus, Type 2, Coronary Artery Disease","enrollment":105},{"nctId":"NCT03606642","phase":"PHASE2","title":"SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy","status":"TERMINATED","sponsor":"HonorHealth Research Institute","startDate":"2018-11-19","conditions":"Coronary Artery Disease, Atherosclerosis, Stent Placement","enrollment":50},{"nctId":"NCT03729401","phase":"PHASE4","title":"Personalization of Long-Term Antiplatelet Therapy - RAPID EXTEND","status":"SUSPENDED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2019-08-22","conditions":"Coronary Artery Disease, Myocardial Infarction","enrollment":390},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT06484647","phase":"","title":"Comparing T-stenting And Minimal Protrusion With External Minicrush for Treatment of Complex Coronary Bifurcation","status":"RECRUITING","sponsor":"San Luigi Gonzaga Hospital","startDate":"2024-06-01","conditions":"Coronary Artery Disease, Ischemic Heart Disease, Chronic Coronary Syndrome","enrollment":382},{"nctId":"NCT06013020","phase":"PHASE4","title":"Century Clot-Guided Prophylactic Rivaroxaban for Post STEMI Complicating Left Ventricular Thrombus","status":"RECRUITING","sponsor":"Zunyi Medical College","startDate":"2024-04-01","conditions":"STEMI - ST Elevation Myocardial Infarction","enrollment":374},{"nctId":"NCT05223335","phase":"PHASE4","title":"Clopidogrel Monotherapy in Patients With High Bleeding Risk","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2022-03-29","conditions":"Bleeding Complications","enrollment":98},{"nctId":"NCT05116995","phase":"PHASE4","title":"Differential EFfects of Dual antIplatelet and Dual aNtithrombotic thErapy on Hemostasis in Chronic Coronary Syndrome Patients","status":"UNKNOWN","sponsor":"Nova Scotia Health Authority","startDate":"2021-11-01","conditions":"Thrombosis, Myocardial Infarction","enrollment":30},{"nctId":"NCT05936606","phase":"NA","title":"Tailored Anti-platelet Therapy After DES Implantation in High-risk Patients","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2023-08-16","conditions":"Coronary Artery Disease","enrollment":3434},{"nctId":"NCT04981041","phase":"PHASE4","title":"Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI","status":"UNKNOWN","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2021-12-16","conditions":"Acute Coronary Syndrome, Atrial Fibrillation","enrollment":2334},{"nctId":"NCT03251859","phase":"PHASE3","title":"Effectiveness of Lower Maintenance Dose of Ticagrelor Early After Myocardial Infarction (ELECTRA) Pilot Study","status":"COMPLETED","sponsor":"Collegium Medicum w Bydgoszczy","startDate":"2017-08-11","conditions":"Myocardial Infarction","enrollment":52},{"nctId":"NCT05779059","phase":"PHASE3","title":"Prasugrel Or Ticagrelor De-escalation in NSTE-ACS","status":"UNKNOWN","sponsor":"Collegium Medicum w Bydgoszczy","startDate":"2023-04-01","conditions":"Non ST Segment Elevation Acute Coronary Syndrome, Non-ST-Segment Elevation Myocardial Infarction (NSTEMI), Unstable Angina","enrollment":50},{"nctId":"NCT04766437","phase":"PHASE2","title":"Optical Coherence Tomography-Guided PCI With Single-Antiplatelet Therapy","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2021-02-19","conditions":"Non ST Segment Elevation Acute Coronary Syndrome","enrollment":75},{"nctId":"NCT01944800","phase":"PHASE4","title":"Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2013-09-15","conditions":"Acute Coronary Syndrome (ACS)","enrollment":4018},{"nctId":"NCT05643586","phase":"PHASE4","title":"Effects of Ticagrelor Versus Prasugrel on Coronary Microcirculation in Patients Undergoing Elective Percutaneous Coronary Intervention: Results of the PROtecting MICROcirculation During Coronary Angioplasty (PROMICRO)-3 Randomised Study","status":"COMPLETED","sponsor":"Germano Di Sciascio","startDate":"2017-12-01","conditions":"Coronary Artery Disease","enrollment":50},{"nctId":"NCT04739384","phase":"PHASE3","title":"Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg in Elderly Patients With ACS","status":"COMPLETED","sponsor":"Federico II University","startDate":"2021-04-01","conditions":"Acute Coronary Syndrome, STEMI, NSTEMI","enrollment":50},{"nctId":"NCT04568083","phase":"","title":"Patient Characteristics, Persistence to Treatment and Outcome Events in Patients Treated With Ticagrelor 60 mg After Myocardial Infarction in Real-world Clinical Practice","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-09-25","conditions":"Myocardial Infarction (MI)","enrollment":7035},{"nctId":"NCT05283356","phase":"PHASE4","title":"Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation","status":"UNKNOWN","sponsor":"Fundacin Biomedica Galicia Sur","startDate":"2022-01-21","conditions":"Severe Aortic Valve Stenosis, Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement (TAVR)","enrollment":1206},{"nctId":"NCT05183178","phase":"PHASE4","title":"Switching From Ticagrelor to Prasugrel in Patients With Acute Coronary Syndrome","status":"UNKNOWN","sponsor":"Vastra Gotaland Region","startDate":"2022-02-01","conditions":"Acute Coronary Syndrome","enrollment":16000},{"nctId":"NCT04331145","phase":"PHASE4","title":"Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation","status":"COMPLETED","sponsor":"Andres Iñiguez Romo","startDate":"2020-06-23","conditions":"Symptomatic Aortic Stenosis","enrollment":40},{"nctId":"NCT02251249","phase":"PHASE4","title":"Impairment of Gastric Emptying During Acute Phase of Myocardial Infarction. Impact on Oral Antiplatelet Treatment Efficacy. The GASTRIM Study.","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2014-12-08","conditions":"Impairment of Gastric Emptying, Acute Phase of Myocardial Infarction","enrollment":23},{"nctId":"NCT02539160","phase":"PHASE4","title":"Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-02","conditions":"Coronary Artery Disease, Diabetes Mellitus","enrollment":101},{"nctId":"NCT05210595","phase":"PHASE4","title":"Optimal Dosage of Ticagrelor in Korean Patients With AMI","status":"UNKNOWN","sponsor":"Dong-A University","startDate":"2022-01-01","conditions":"Acute Myocardial Infarction, Ticagrelor","enrollment":120},{"nctId":"NCT03437044","phase":"PHASE4","title":"Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI","status":"COMPLETED","sponsor":"University of Florida","startDate":"2018-03-14","conditions":"Diabetes Mellitus, Type 2, Coronary Artery Disease","enrollment":40},{"nctId":"NCT04695106","phase":"PHASE4","title":"Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI","status":"RECRUITING","sponsor":"Medical University of Gdansk","startDate":"2021-10-25","conditions":"Atrial Fibrillation, Antithrombotic Therapy, Acute Coronary Syndrome","enrollment":2230},{"nctId":"NCT04734353","phase":"PHASE4","title":"Prasugrel 5 mg vs. Ticagrelor 60 mg in CHIP (E5TION)","status":"UNKNOWN","sponsor":"Gyeongsang National University Hospital","startDate":"2020-01-15","conditions":"Coronary Artery Disease","enrollment":492},{"nctId":"NCT02618837","phase":"PHASE4","title":"Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers","status":"UNKNOWN","sponsor":"University of Padova","startDate":"2015-12-14","conditions":"Unstable Angina or Non ST Elevated Myocardial Infarction","enrollment":2520},{"nctId":"NCT03489863","phase":"PHASE4","title":"Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study","status":"COMPLETED","sponsor":"University of Florida","startDate":"2018-05-30","conditions":"Coronary Artery Disease","enrollment":14},{"nctId":"NCT02944123","phase":"PHASE3","title":"Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR)","status":"COMPLETED","sponsor":"Dong-A University","startDate":"2016-09","conditions":"Acute Coronary Syndrome","enrollment":120},{"nctId":"NCT02866175","phase":"PHASE3","title":"Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2017-02-24","conditions":"Atrial Fibrillation","enrollment":1506},{"nctId":"NCT04069234","phase":"PHASE3","title":"Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention.","status":"WITHDRAWN","sponsor":"Region Skane","startDate":"2019-09-15","conditions":"Diabetes Mellitus, Microvascular Coronary Artery Disease","enrollment":""},{"nctId":"NCT01991795","phase":"PHASE3","title":"A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-02-10","conditions":"Diabetes Mellitus, Type 2","enrollment":19271},{"nctId":"NCT03454841","phase":"","title":"Daily Variability of Platelet Aggregation in Patients With Myocardial Infarction Treated With Prasugrel and Ticagrelor","status":"COMPLETED","sponsor":"Collegium Medicum w Bydgoszczy","startDate":"2018-02-26","conditions":"Acute Myocardial Infarction","enrollment":73},{"nctId":"NCT04267224","phase":"","title":"Early Versus Late Loading of Ticagrelol in Patients With STEMI","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2020-03-01","conditions":"Myocardial Infarction","enrollment":800},{"nctId":"NCT02376283","phase":"PHASE4","title":"P3AMI Antiplatelet Trial","status":"COMPLETED","sponsor":"The Royal Wolverhampton Hospitals NHS Trust","startDate":"2015-03-09","conditions":"Heart Attack","enrollment":87},{"nctId":"NCT04060914","phase":"PHASE4","title":"LOwer Maintenance Dose TICagrelor in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention","status":"UNKNOWN","sponsor":"Beijing Anzhen Hospital","startDate":"2019-08-30","conditions":"Antiplatelet Therapy, Coronary Artery Disease, Percutaneous Coronary Intervention","enrollment":225},{"nctId":"NCT02302508","phase":"PHASE4","title":"Pharmacokinetics of Antiplatelet Drugs in Diabetic pAtients","status":"WITHDRAWN","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2019-09-01","conditions":"Diabetes","enrollment":""},{"nctId":"NCT03435133","phase":"NA","title":"Prasugrel vs. Ticagrelor on Myocardial Injury in STEMI","status":"COMPLETED","sponsor":"AORTICA Group","startDate":"2015-11-23","conditions":"ST Elevation Myocardial Infarction","enrollment":61},{"nctId":"NCT03881943","phase":"PHASE4","title":"Ticagrelor Monotherapy Compared to Aspirin Monotherapy in Patients With History of ACS","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2017-01","conditions":"Acute Coronary Syndrome","enrollment":200},{"nctId":"NCT03387826","phase":"PHASE4","title":"Low Dose Ticagrelor Versus Low Dose Prasugrel in Patients With Prior Myocardial Infarction","status":"COMPLETED","sponsor":"Attikon Hospital","startDate":"2018-01-11","conditions":"Myocardial Infarction, Diabetes Mellitus, Coronary Artery Disease","enrollment":20},{"nctId":"NCT02327624","phase":"PHASE4","title":"STEEL Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2015-06","conditions":"Coronary Artery Disease","enrollment":180},{"nctId":"NCT02044146","phase":"PHASE2, PHASE3","title":"A Pharmacodynamic Study of a Personalized Strategy for P2Y12 Inhibition Versus Ticagrelor in Reducing Ischemic and Bleeding Risk","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2014-09","conditions":"Acute Coronary Syndrome, Percutaneous Coronary Intervention","enrollment":120},{"nctId":"NCT01589978","phase":"PHASE4","title":"PROMUS Element Plus US Post-Approval Study","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2012-05","conditions":"Coronary Artery Disease","enrollment":2681},{"nctId":"NCT02422888","phase":"PHASE4","title":"Reducing Micro Vascular Dysfunction in Acute Myocardial Infarction by Ticagrelor","status":"UNKNOWN","sponsor":"Amsterdam UMC, location VUmc","startDate":"2015-05","conditions":"Myocardial Infarction","enrollment":110},{"nctId":"NCT03330223","phase":"","title":"Effect of Haemodialysis on the Efficacy of Antiplatelet Agents","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2017-11-10","conditions":"Renal Failure, Coronary Artery Disease, Hemolysis","enrollment":60},{"nctId":"NCT03273075","phase":"PHASE4","title":"Add-on Cangrelor in STEMI-triggered Cardiac Arrest","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2017-09","conditions":"Cardiopulmonary Arrest With Successful Resuscitation, ACS - Acute Coronary Syndrome, Hypothermia, Induced","enrollment":60},{"nctId":"NCT02075125","phase":"PHASE3","title":"Prasugrel and Ticagrelor in ST-segment Elevation Myocardial Infarction","status":"TERMINATED","sponsor":"Dong-A University","startDate":"2014-01","conditions":"ST-Segment Elevation Myocardial Infarction","enrollment":39},{"nctId":"NCT02808767","phase":"PHASE4","title":"Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Faculty Hospital Kralovske Vinohrady","startDate":"2013-01","conditions":"Myocardial Infarction, Angioplasty, Balloon, Coronary, Platelet Aggregation Inhibitors","enrollment":1226},{"nctId":"NCT02663713","phase":"PHASE4","title":"A Randomized, Pharmacodynamic Comparison of Low Dose Ticagrelor to Clopidogrel in Patients With Prior Myocardial Infarction","status":"COMPLETED","sponsor":"University of Patras","startDate":"2017-01","conditions":"Myocardial Infarction, Diabetes Mellitus, Renal Disease","enrollment":20},{"nctId":"NCT02215993","phase":"PHASE4","title":"Sampling P2Y12 Receptor Inhibition With Prasugrel and Ticagrelor in Patients Submitted to Thrombolysis","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2013-07","conditions":"Acute Coronary Syndrome, Platelet Function","enrollment":50},{"nctId":"NCT03016611","phase":"PHASE4","title":"Chewing Ticagrelor Versus Prasugrel in ST-elevation Myocardial Infarction - A Platelet Reactivity Study","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2017-02","conditions":"Acute Coronary Syndrome, STEMI","enrollment":100},{"nctId":"NCT02064985","phase":"PHASE4","title":"Ticagrelor China Pharmacokinetic/Pharmacodynamic Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-02","conditions":"Stable Coronary Heart Disease (CHD)","enrollment":61},{"nctId":"NCT02507323","phase":"PHASE2","title":"Ticagrelor vs. Prasugrel Effects on Infarct Size","status":"WITHDRAWN","sponsor":"Yochai Birnbaum","startDate":"2016-02","conditions":"Cardiovascular Disease","enrollment":""},{"nctId":"NCT01225562","phase":"PHASE3","title":"Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-10","conditions":"Myocardial Infarction, Cardiovascular Death, Atherothrombosis","enrollment":21379},{"nctId":"NCT01992523","phase":"PHASE3","title":"Mojito Study (Mashed Or Just Integral Pill of TicagrelOr ? )","status":"COMPLETED","sponsor":"David Antoniucci","startDate":"2013-11","conditions":"Acute Coronary Syndrome, Adverse Reaction to Antiplatelet Agent","enrollment":82},{"nctId":"NCT02046486","phase":"PHASE4","title":"OraL Crushed and dIspersed Ticagrelor 180mg Compared to Whole Tablets of eQUal Dose in STEMI Patients unDergoing Primary PCI: a Pharmacokinetic/Pharmacodynamic Study (the LIQUID Study)","status":"COMPLETED","sponsor":"University of Patras","startDate":"2014-01","conditions":"ST Elevation Myocardial Infarction","enrollment":20},{"nctId":"NCT01510171","phase":"PHASE4","title":"Rapid Activity of Platelet Inhibitor Drugs Study","status":"COMPLETED","sponsor":"Careggi Hospital","startDate":"2012-01","conditions":"ST-segment Elevation Myocardial Infarction","enrollment":50},{"nctId":"NCT01805570","phase":"PHASE4","title":"Rapid Activity of Platelet Inhibitor Drugs Study 2","status":"COMPLETED","sponsor":"David Antoniucci","startDate":"2012-11","conditions":"Myocardial Infarction","enrollment":50},{"nctId":"NCT01766466","phase":"PHASE2","title":"Cangrelor Ticagrelor Transition Study","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2013-01","conditions":"Coronary Artery Disease","enrollment":12},{"nctId":"NCT01876797","phase":"PHASE1","title":"PKPD Study of Ticagrelor and Prasugrel in Healthy Korean Males","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2013-07","conditions":"Healthy","enrollment":12},{"nctId":"NCT01456364","phase":"PHASE4","title":"Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing","status":"UNKNOWN","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2011-09","conditions":"Coronary Heart Disease","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":59,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ticagrelor 60","genericName":"Ticagrelor 60","companyName":"Sheffield Teaching Hospitals NHS Foundation Trust","companyId":"sheffield-teaching-hospitals-nhs-foundation-trust","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ticagrelor 60 mg is a P2Y12 platelet receptor antagonist that inhibits platelet aggregation and reduces thrombotic events. Used for Acute coronary syndrome (ACS) for prevention of thrombotic cardiovascular events, Secondary prevention of atherothrombotic events in patients with prior myocardial infarction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}